GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » Institutional Ownership

GLMD (Galmed Pharmaceuticals) Institutional Ownership : 2.70% (As of Apr. 23, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Galmed Pharmaceuticals's institutional ownership is 2.70%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Galmed Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Galmed Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 72.46%.


Galmed Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Galmed Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galmed Pharmaceuticals Institutional Ownership Chart

Galmed Pharmaceuticals Historical Data

The historical data trend for Galmed Pharmaceuticals can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 0.35 0.35 0.29 0.12 0.11 0.10 0.10 0.10 0.10 0.10

Galmed Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Galmed Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
16 Abba Hillel Road, Ramat Gan, ISR, 5250608
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.